



TECHNICAL ALERT No. 17-13

Bahamas National Requirements Rev.9 Corrigendum

1. Introduction

- 1.1. Paragraph 24.8.2(i) of the Bahamas National Requirements (Revision 9) provides a link to the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) "General Sales List" medicines that may be sold to passengers on board ships registered in The Bahamas.
- 1.2. The Bahamas Maritime Authority wishes to bring the information referenced in Paragraph 1.1 to the attention of interested parties.

2. Updated MHRA General Sales List

- 2.1. The BMA has obtained an updated list of current UK marketing authorisations for GSL (General Sales List) medicines from the MHRA.
- 2.2. Products on the GSL, and products containing the same substances, may be sold to passengers on board ships registered in The Bahamas, subject to the following conditions:
 - i. Medicines must be listed in the GSL;
 - ii. Pain relief medication should have a maximum pack size of 16 tablets or capsules and have a maximum strength of 200mg for ibuprofen, 325mg for aspirin (acetylsalicylic acid) and 500mg for paracetamol (acetaminophen).
 - iii. Sales of pain relief medication should be limited to two (2) packs in any one transaction;
 - iv. The sale of products containing any amount of Codeine is not permitted
- 2.3. The above restrictions do not apply to any medicines provided by the Master, ship's doctor (where carried) or medical officer.
- 2.4. The updated list is available to download [here](http://www.bahamasmaritime.com/wp-content/uploads/2017/11/GSL-medicines-lsting.pdf)¹.

¹ <http://www.bahamasmaritime.com/wp-content/uploads/2017/11/GSL-medicines-lsting.pdf>

3. Validity

3.1. This alert is valid until further notice.

4. Revision History

Rev.0 (13 November 2017) – First issue